Bitcoin (CRYPTO: BTC) is worth over $50,000 once again, spurring bulls to act once again.
What Happened: According to CoinMarketCap data, Bitcoin brushed the $51,000 price level after seeing a price increase of over 5% from its 24-hour low of $48,457 up to $50,912.
According to market analyst Michaël Van De Poppe, the final resistance before Bitcoin can resume the bullish trend is located in the $50,712 area, while the RSI currently standing at 61.69 already invalidated the bearish divergence signal by falling under 70.
What Else: Van De Poppe also explained in his recent YouTube video that when “Bitcoin is breaking out of this $51,000 level, the chances are that we just get one vertical candle towards $58,000, or even $60,000.”
In this case, he believes that altcoins would heavily lose value against Bitcoin and not keep the pace.
The buy and sell levels contained in the order book of the world's top crypto exchange Binance show a particularly high sell volume at the $51,000 level, with another couple concentrated seller areas before $52,000. Then, there is no comparable concentrated seller aria until the $60,000 area.
Best Value Stocks To Invest In Right Now: Immunomedics, Inc.(IMMU)
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases. The company is developing Yttrium-90-labeled clivatuzumab tetraxetan, which is in Phase III registration study used for the treatment of pancreatic cancer. It is also developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAM5-SN-38 ADC that is in Phase II trials for the treatment of metastatic colorectal cancer; and epratuzumab, which is in two Phase III clinical trials for the treatment of systemic lupus erythematosus. Its early-stage products include Veltuzumab, a humanized monoclonal antibody targeting CD20 receptors on B lymphocytes for the treatment of non-Hodgkin lymphoma (NHL) and autoimmune diseases; Milatuzumab, a humanized monoclonal antibody targeting tumors that expresses the CD74 antigen, which is in Phase 1 studies; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled anti-CD22 investigational product candidate for patients with NHL or acute lymphoblastic leukemia; and IMMU-114, a novel humanized antibody for the treatment of patients with B-cell cancers. The company also provides LeukoScan, a diagnostic imaging product for diagnostic imaging to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
